INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,031,766 | +189.4% | 702,900 | +93.1% | 0.03% | +125.0% |
Q4 2022 | $4,503,521 | +1063.7% | 364,068 | +1212.6% | 0.01% | +1100.0% |
Q3 2022 | $387,000 | +170.6% | 27,736 | +167.2% | 0.00% | – |
Q2 2022 | $143,000 | -54.6% | 10,380 | -46.3% | 0.00% | -100.0% |
Q4 2021 | $315,000 | -91.2% | 19,333 | -92.0% | 0.00% | -93.3% |
Q3 2021 | $3,575,000 | +945.3% | 240,731 | +4326.0% | 0.02% | +275.0% |
Q1 2020 | $342,000 | -95.4% | 5,439 | -91.0% | 0.00% | -91.1% |
Q4 2019 | $7,509,000 | -51.0% | 60,595 | -52.3% | 0.04% | -35.7% |
Q3 2018 | $15,313,000 | +106.1% | 127,000 | +43.4% | 0.07% | +112.1% |
Q2 2018 | $7,429,000 | +150.7% | 88,534 | +74.6% | 0.03% | +266.7% |
Q4 2017 | $2,963,000 | -63.9% | 50,716 | -64.1% | 0.01% | -71.9% |
Q3 2017 | $8,207,000 | -40.4% | 141,400 | +24.4% | 0.03% | -43.9% |
Q2 2017 | $13,766,000 | +497.0% | 113,704 | +435.7% | 0.06% | +375.0% |
Q4 2016 | $2,306,000 | -1.4% | 21,227 | +49.5% | 0.01% | -14.3% |
Q3 2016 | $2,338,000 | – | 14,202 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |